NCT03708965View on ClinicalTrials.gov

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Mucopolysaccharidosis II
Interventions
DRUG

JR-141

IV infusion (lyophilized powder)

Trial Locations (2)

Unknown

Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre

Igeim - Unifesp, São Paulo

Sponsors
All Listed Sponsors
lead

JCR Pharmaceuticals Co., Ltd.

INDUSTRY